[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors]

Korean J Gastroenterol. 2008 Aug;52(2):80-5.
[Article in Korean]

Abstract

Background/aims: Conflicting results have been reported whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H. pylori) eradication treatment compared with patients with peptic ulcer diseases (PUD). The aim of this study was to evaluate any difference in H. pylori eradication rates between patients with NUD and PUD according to each proton pump inhibitor (PPI).

Methods: From September, 2004 to April, 2007, we retrospectively reviewed 2,297 patients with NUD (1,050 patients) or PUD (1,247 patients) infected with H. pylori. All patients received a standard 1 week triple therapy comprising of one of the five PPIs (pantoprazole, esomeprazole, omeprazole, lansoprazole, rabeprazole), clarithromycin and amoxicillin. The follow-up H. pylori test was performed 4 weeks after the completion of therapy.

Results: There was no significant difference in the eradication rates between the two groups. In comparison of eradication rates according to PPI, omeprazole- based triple therapy group showed higher eradication rate than other groups in patients with NUD, but not in patients with PUD.

Conclusions: This study failed to show any difference in H. pylori eradication rate between patients with NUD and PUD. There is no convincing evidence that the eradication rate may be affected by different PPI.

Publication types

  • Comparative Study

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use
  • Adult
  • Amoxicillin / administration & dosage
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Ulcer Agents / administration & dosage
  • Clarithromycin / administration & dosage
  • Data Interpretation, Statistical
  • Drug Therapy, Combination
  • Dyspepsia / drug therapy*
  • Dyspepsia / etiology
  • Dyspepsia / microbiology
  • Enzyme Inhibitors / therapeutic use
  • Esomeprazole
  • Female
  • Helicobacter Infections / complications
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori*
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use
  • Pantoprazole
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / etiology
  • Peptic Ulcer / microbiology
  • Proton Pump Inhibitors / therapeutic use
  • Rabeprazole

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Enzyme Inhibitors
  • Proton Pump Inhibitors
  • Lansoprazole
  • Rabeprazole
  • Amoxicillin
  • Pantoprazole
  • Clarithromycin
  • Omeprazole
  • Esomeprazole